Artelo Biosciences, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Artelo Biosciences, Inc. (Nasdaq: ARTL) is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, to address unmet needs in cancer, pain, inflammation, anxiety, dermatologic conditions and anorexia. The company's core product candidates include ART27.13, a synthetic CB1/CB2 receptor agonist in Phase 2 for cancer-related anorexia and weight loss via the CAReS study; ART26.12, a FABP5 inhibitor advancing toward clinical trials for chemotherapy-induced peripheral neuropathy and pain; and ART12.11, a synthetic CBD cocrystal in preclinical development for inflammatory bowel disease, anxiety, depression, epilepsy and insomnia. Founded in 2011 and headquartered in Solana Beach, California, with additional operations in La Jolla, California; Alderley Edge, United Kingdom; and Dublin, Ireland, Artelo targets oncology supportive care, neurology and dermatology markets primarily in the United States and Europe. Recent developments include a $3 million funding round in September 2025 to support Phase 2 data release for ART27.13 and initiation of a multiple ascending dose study for ART26.12; a $1.425 million at-the-market private placement in June 2025 to fund clinical data releases and R&D operations through late 2026, including a strategic $250,000 investment in SOL cryptocurrency for data infrastructure; completion of Phase 1b/2a trials for ART27.13 as of late 2024; and ongoing preclinical advancement of ART26.12 with data presentations.
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Decrease in Short Interest
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Artelo Biosciences Stock Soars After Withdrawing SEC Filing
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
Nano-Cap Artelo Biosciences Stock Explodes — Glaucoma Study Collaboration Ignites Rally
Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum